Enerzair capsules for inhalation contains three active substances called indacaterol, glycopyrronium and mometasone furoate. Indacaterol and glycopyrronium belong to a group of medicines called ...

All LABAs are associated with an increased risk of asthma-related deaths. Indacaterol is indicated for patients with COPD and not for patients with asthma. Indacaterol should not be used for ...

Ultibro capsules for inhalation contain the active ingredients, indacaterol maleate and glycopyrronium bromide (glycopyrrolate) in a capsule form. The capsules are for oral inhalation only.

QVM149 is a triple therapy consisting of indacaterol (acetate), glycopyrronium (bromide) and mometasone (furoate), which is being developed as a daily inhaled treatment for asthma delivered via ...

Review the side-effects of Indacaterol as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...